Table 2 Characteristics of included trials, overall and subsetted by trials with and without results reported by the start of result searches 15 August 2021. Cross-registrations refer to registrations in 2 or more registries; multiple registrations of the same trial in the same registry are not counted as cross-registrations. Top interventions refer to most common individual interventions. The “Other” trial status includes trials in “Ongoing” and any other non-completed statuses
From: Dissemination of Registered COVID-19 Clinical Trials (DIRECCT): a cross-sectional study
Characteristic | Overalla N = 1643 | Trials with resultsa N = 402 | Trials without resultsa N = 1241 |
|---|---|---|---|
Target enrollment | 100 (48, 253) | 106 (43, 291) | 100 (50, 250) |
Cross-registered | 205 (12%) | 53 (13%) | 152 (12%) |
Multinational | 102 (6.2%) | 32 (8.0%) | 70 (5.6%) |
Randomized | 1313 (80%) | 311 (77%) | 1002 (81%) |
Trial phase | |||
Not applicableb | 461 (28%) | 122 (30%) | 339 (27%) |
Phase 1 | 78 (4.7%) | 15 (3.7%) | 63 (5.1%) |
Phase 1/Phase 2 | 77 (4.7%) | 30 (7.5%) | 47 (3.8%) |
Phase 2 | 429 (26%) | 89 (22%) | 340 (27%) |
Phase 2/Phase 3 | 129 (7.9%) | 29 (7.2%) | 100 (8.1%) |
Phase 3 | 306 (19%) | 82 (20%) | 224 (18%) |
Phase 3/Phase 4 | 7 (0.4%) | 1 (0.2%) | 6 (0.5%) |
Phase 4 | 156 (9.5%) | 34 (8.5%) | 122 (9.8%) |
Trial status | |||
Completed | 472 (29%) | 206 (51%) | 266 (21%) |
Terminated | 81 (4.9%) | 24 (6.0%) | 57 (4.6%) |
Other | 1090 (66%) | 172 (43%) | 918 (74%) |
Pandemic phase | |||
Jan 2020–Jun 2020 | 282 (17%) | 102 (25%) | 180 (15%) |
July 2020–Dec 2020 | 672 (41%) | 197 (49%) | 475 (38%) |
Jan 2021–Jun 2021 | 689 (42%) | 103 (26%) | 586 (47%) |
Top 5 interventions | |||
Hydroxychloroquine | 138 (35%) | 41 (33%) | 97 (36%) |
Convalescent plasma | 118 (30%) | 38 (30%) | 80 (29%) |
Stem cells (mesenchymal) | 50 (13%) | 11 (8.8%) | 39 (14%) |
Azithromycin | 46 (12%) | 13 (10%) | 33 (12%) |
Ivermectin | 46 (12%) | 22 (18%) | 24 (8.8%) |